This website uses cookies

We use cookies and website tracking tools to provide you with the best online experience. Learn more in our privacy statement.

if you accept, your choice will be valid until cancellation.

If you disallow cookies, functionality of our website might be limited.


HIH News

Personalized therapy for patients with malignant brain tumors

Two years after its introduction, the Molecular Tumor Board (MTB) at the University Hospital Tübingen has been highly frequented by patients with brain tumors. “The interdisciplinary collaboration at the MTB allows us to develop individualized forms of therapy for our patients,” says Prof. Dr. Dr. Ghazaleh Tabatabai, head of the Interdisciplinary Section of Neuro-Oncology at the University Hospital Tübingen and the Hertie Institute for Clinical Brain Research (HIH). The neurooncologist is one of the co-founders of the Molecular Tumor Board, which was established in 2016. In an interview with the Hertie Foundation, Tabatabai talks about the challenges of her everyday work.

Prof. Dr. Dr. Tabatabai and one of her research group members in the lab (Photo: Rappers / HIH)